查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402586

血栓溶解治療市場：依藥物類型、依適應症、依最終用戶、依給藥方法、依分銷管道、依患者年齡、依包裝類型、依應用、依劑型、依地區

Fibrinolytic Therapy Market, By Drug Type, By Indication, By End User, By Administration (Intravenous, Intra-arterial ), By Distribution Channel, By Patient Age, By Packaging Type, By Application, By Dosage Form, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球血栓溶解治療市場預計將從2023年的349.6億美元增加到2030年的450.8億美元，2023年至2030年的年複合成長率（CAGR）為3.7%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 349.6億美元
實際資料 2018-2021 預測期 2023-2030
預測期複合年成長率 3.70% 2030年市場規模預測 450.8億美元
圖 1. 2023 年依地區分類的血栓溶解治療全球市場佔有率(%)
血栓溶解治療市場-IMG1

血栓溶解治療用於溶解可能導致心臟病和中風的血栓。溶栓治療是一種挽救生命的治療方法，但如果存在潛在的健康問題，則可能會失敗並導致其他嚴重的疾病和病理。溶栓治療通常透過靜脈注射進行。當一個人出現中風或心臟病發作症狀並且其他治療（例如抗凝血劑或類固醇）無效時，可以使用溶栓療法。它可以在家中或在醫院進行。組織纖維蛋白溶酶原活化劑或Alteplase是一種分解纖維蛋白和其他在體內形成血栓的物質的藥物，最常用於溶栓治療。Tenecteplase對某些患者也有效，可以口服。

市場動態

由於創傷和道路事故的增加，抗纖溶藥物的需求不斷增加，這推動了血栓溶解治療市場的成長。這些藥物擴大用於口腔出血治療，主要用於治療月經出血（月經量多），預計將進一步推動市場成長。此外，嚴重交通事故和創傷案件數量的增加正在創造對抗纖溶藥物的需求，推動市場成長。此外，這些藥物擴大用於治療血友病和其他疾病，如血小板功能障礙、馮維勒布蘭德病以及A型血友病和乙型血友病，進一步推動了市場的成長。

全球血栓溶解治療市場也受到導致血栓的心血管、神經和肺部疾病盛行率上升的推動。根據世界衛生組織 (WHO) 統計，心血管疾病每年導致超過 1,790 萬人死亡。此外，越來越多的老年人口更容易患此類疾病，也促進了市場的成長。然而，纖溶藥物的高價格、嚴格的監管以及與治療相關的出血風險正在阻礙市場擴張。該市場提供了開發有效重組、合成類似物和混合分子的機會，這些分子具有更高的特異性、增強的纖維蛋白特異性並降低出血風險。

然而，這些藥物的高價格是阻礙市場成長的主要因素。

本研究的主要特點

  • 本報告對全球血栓溶解治療市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030）的市場規模和複合年成長率。
  • 本報告還揭示了各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 本報告根據公司亮點、產品系列、主要亮點、業績和策略等參數，介紹了全球血栓溶解治療市場的主要企業。
  • 該報告的見解使行銷人員和經營團隊負責人就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球血栓溶解治療市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球血栓溶解治療市場的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
    • 促進要素
  • 心血管疾病發生率增加
  • 老年人口增加
  • 技術進步
  • 使用醫療保健設施
    • 壓制
  • 對某些患者族群的療效有限
  • 出血併發症的風險
  • 替代治療方法的可用性
  • 時間敏感性和門到針延遲
    • 機會
  • 新興市場
  • 聯合治療
  • 遠端醫療和遠端醫療
  • 個人化醫療
    • 主要亮點
    • 監管場景
    • 最近的趨勢
    • 產品發布/核准
    • PEST分析
    • 波特的分析
    • 合併、收購和合作

第4章全球血栓溶解治療市場－冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章全球血栓溶解治療市場，依藥物類型，2018-2030

  • Alteplase
  • Reteplase
  • 替奈普酶
  • 鏈球菌激酶
  • 阿尼普酶
  • 尿激酶

第 6 章 2018-2030 年全球血栓溶解治療市場（依適應症）

  • 急性缺血性腦中風
  • 急性心肌梗塞
  • 深層靜脈栓塞症
  • 周圍動脈血栓症
  • 其他動脈血栓症

第 7 章 全球血栓溶解治療市場，依最終使用者分類，2018-2030 年

  • 醫院
  • 門診手術中心
  • 專科診所
  • 其他

第8章全球血栓溶解治療市場，依給藥方法，2018-2030

  • 靜脈注射(IV)
  • 動脈內 (IA)

第9章全球血栓溶解治療市場，依通路，2018-2030

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章2018-2030年全球血栓溶解治療市場（依病患年齡）

  • 成年患者
  • 兒童患者

第11章全球血栓溶解治療市場，依包裝類型，2018-2030

  • 管瓶
  • 安瓿
  • 預填充式注射器

第12章全球血栓溶解治療市場，依應用分類，2018-2030

  • 緊急醫療護理
  • 介入性心臟病學
  • 血栓症形成的治療
  • 其他

第13章全球血栓溶解治療市場，依劑型，2018-2030

  • 用於重構的凍乾粉
  • 注射液

第14章2018-2030年全球血栓溶解治療市場（依地區）

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 南非
  • 中部非洲
  • 北非

第15章競爭形勢

  • 公司簡介
    • Genentech, Inc.（Roche）
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novarts AG
    • AstraZeneca PLC
    • Johnson &Johnson
    • Daiichi Sankyo Company, Limited
    • Merck &Co., Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation

第16章 章節

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5879

Global fibrinolytic therapy market is projected to reach US$ 45.08 Bn by 2030, from US$ 34.96 Bn in 2023, at a compound annual growth rate (CAGR) of 3.7% during 2023-2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 34.96 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.70% 2030 Value Projection: US$ 45.08 Bn
Figure 1. Global Fibrinolytic Therapy Market Share (%), By Region, 2023
Fibrinolytic Therapy Market - IMG1

Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it fails in underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an intravenous line. It is used when symptoms of a stroke or heart attack are present and the patient is not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase is a drug that breaks down fibrin and other substances that create clots in the body that is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can also be given by mouth.

Market Dynamic:

The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling the market growth. Furthermore, rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth.

Also, the global fibrinolytic therapy market is driven by the rising prevalence of cardiovascular diseases, neurological disorders and pulmonary diseases causing blood clots. As per World Health Organization (WHO), cardiovascular diseases accounts for over 17.9 Mn deaths annually. Moreover, growing geriatric population prone to such diseases contributes to the market growth. However, high costs of fibrinolytic drugs, stringent regulations, and risk of bleeding associated with the therapy inhibits the market expansion. The market provides opportunities for development of effective recombinant variants, synthetic analogs, and hybrid molecules with greater specificity, enhanced fibrin specificity and reduced bleeding risks.

However, the high price of these drugs is a key factor that can hinder the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global fibrinolytic therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market

Detailed Segmentation:

  • Global Fibrinolytic Therapy Market, By Drug Type:
    • Alteplase
    • Reteplase
    • Tenecteplase
    • Streptokinase
    • Anistreplase
    • Urokinase
  • Global Fibrinolytic Therapy Market, By Indication:
    • Acute Ischemic Stroke
    • Acute Myocardial Infarction
    • Deep Vein Thrombosis
    • Peripheral Arterial Thrombosis
    • Other Arterial Thrombosis
  • Global Fibrinolytic Therapy Market, By End User:
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Others
  • Global Fibrinolytic Therapy Market, By Administration:
    • Intravenous (IV)
    • Intra-arterial (IA)
  • Global Fibrinolytic Therapy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Fibrinolytic Therapy Market, By Patient Age:
    • Adult Patients
    • Pediatric Patients
  • Global Fibrinolytic Therapy Market, By Packaging Type:
    • Vials
    • Ampoules
    • Pre-filled Syringes
  • Global Fibrinolytic Therapy Market, By Application:
    • Emergency Care
    • Interventional Cardiology
    • Thrombosis Treatment
    • Others
  • Global Fibrinolytic Therapy Market, By Dosage Form:
    • Lyophilized Powder for Reconstitution
    • Solution for Injection
  • Global Fibrinolytic Therapy Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top Companies in the Global Fibrinolytic Market:
    • Genentech, Inc. (Roche)
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novartis AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By End User
    • Market Snippet, By Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Patient Age
    • Market Snippet, By Packaging Type
    • Market Snippet, By Application
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
  • Increasing incidence of cardiovascular diseases
  • Growing geriatric population
  • Technological advancements
  • Access to healthcare facilities
    • Restrain
  • Limited efficacy in certain patient populations
  • Risk of bleeding complications
  • Availability of alternative treatment modalities
  • Time sensitivity and door-to-needle delays
    • Opportunities
  • Emerging markets
  • Combination therapies
  • Telemedicine and remote treatment
  • Personalized medicine
    • Key Highlights
    • Regulatory Scenario
    • Recent Trends
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER's Analysis
    • Mergers, Acquisitions, and Collaborations

4. Global Fibrinolytic Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Fibrinolytic Therapy Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Alteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Reteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Tenacteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Streptokinase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Anistreplase
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Urokinase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Fibrinolytic Therapy Market, By Indication, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Acute Ischemic Stroke
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Acute Myocardial Infarction
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Deep Vein Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Peripheral Arterial Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Other Arterial Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,US$ Bn(US$ Bn)

7. Global Fibrinolytic Therapy Market, By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Speciality Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Fibrinolytic Therapy Market, By Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Intravenous (IV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Intra-arterial (IA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Fibrinolytic Therapy Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

10. Global Fibrinolytic Therapy Market, By Patient Age, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Pediatric Patients

11. Global Fibrinolytic Therapy Market, By Packaging Types, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Ampoules
  • Pre-filled Syringes

12. Global Fibrinolytic Therapy Market, By Application, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Emergency Care
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
  • Interventional Cardiology
  • Thrombosis Treatment
  • Others

13. Global Fibrinolytic Therapy Market, By Dosage Form, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Lyophilized Powder for Reconstitution
  • Solution for Injection

14. Global Fibrinolytic Therapy Market , By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2018 -2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2018-2030,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa

15. Competitive Landscape

  • Company Profile
    • Genentech, Inc. (Roche)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novarts AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation
  • Analyst Views

16. Section

  • References
  • Research Methodology
  • About us